文献速递眼底病与葡萄膜炎

使用腺相关病毒载体的视网膜基因治疗对无脉络膜症患者的疗效与安全性:一项随机临床试验

Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

THOR试验为单中心2期开放标签随机临床试验,纳入6例分子确诊的男性无脉络膜症患者,比较一眼接受AAV2-REP1视网膜下注射与对照眼24个月的最佳矫正视力变化。结果显示治疗眼与对照眼最佳矫正视力变化无显著差异(差值3.7;95%CI -7.2至14.5;P=.43),视网膜敏感度变化亦无显著差异(差值0.6;95%CI -10.2至11.4;P=.74)。共报告28例不良事件,均与手术操作相关,无严重不良事件。

要点

  • 6例男性无脉络膜症患者接受AAV2-REP1单次0.1 mL视网膜下注射(1011个基因组颗粒),对照眼未治疗。
  • 24个月时治疗眼BCVA变化3.7(7.5)vs对照眼0.0(5.1),差值3.7(95%CI -7.2至14.5;P=.43),无显著差异。
  • 共报告28例不良事件,均与手术操作相关,无严重不良事件。

核心结论

  • 在6例参与者中,AAV2-REP1基因治疗与视力维持或改善相关,但与对照眼相比未发现显著差异。
  • 所有安全性问题均与手术操作相关,无严重不良事件。
  • 持续研究可更精确地界定AAV2-REP1基因治疗在无脉络膜症中的疗效与安全性。

研究设计与样本

  • THOR为单中心、2期、开放标签随机临床试验,数据收集时间为2016年1月11日至2018年2月26日。
  • 报告6例分子确诊无脉络膜症男性患者的24个月数据,采用意向性治疗分析。
  • 患者接受单次0.1 mL视网膜下注射1011个基因组颗粒的AAV2-REP1,于玻璃体切除术中注入随机分配接受治疗的一眼。

主要发现

  • 入组时6例男性平均(SD)年龄54.9(4.1)岁。
  • 入组时研究眼平均(SD)BCVA评分60.3(13.4)(约相当于Snellen 20/63),对照眼69.3(20.6)(约相当于Snellen 20/40)。
  • 24个月时治疗眼BCVA变化3.7(7.5),对照眼0.0(5.1),差值3.7(95%CI -7.2至14.5;P=.43)。
  • 视网膜敏感度平均变化治疗眼10.3(5.5)dB,对照眼9.7(4.9)dB,差值0.6(95%CI -10.2至11.4;P=.74)。
  • 共报告28例不良事件,均与手术操作一致(如结膜充血、异物感),无一被视为严重。

关键数值与推荐

  • 主要终点为治疗眼与对照眼从基线至第24个月ETDRS视力表最佳矫正视力变化。
  • 次要终点包括微视野变量、眼底自发荧光变化及频域光学相干断层扫描评估(治疗眼与对照眼从基线至第24个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量为6例参与者。
  • 原文结论指出持续研究可更精确地界定AAV2-REP1基因治疗在无脉络膜症中的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Choroideremia (CHM) is a rare, degenerative, genetic retinal disorder resulting from mutation of the CHM gene, leading to an absence of functional ras-associated binding escort protein 1 (REP1). There is currently no approved treatment for CHM. OBJECTIVE: To assess the safety and efficacy of retinal gene therapy with an adeno-associated virus vector (AAV2) designed to deliver a functional version of the CHM gene (AAV2-REP1) for treatment of patients with choroideremia. DESIGN, SETTING, AND PARTICIPANTS: Tübingen Choroideremia Gene Therapy (THOR) was a single-center, phase 2, open-label randomized clinical trial. Data were collected from January 11, 2016, to February 26, 2018. Twenty-four-month data are reported for 6 men with a molecularly confirmed diagnosis of CHM. Intention-to-treat analysis was used. INTERVENTIONS: Patients received AAV2-REP1 by a single, 0.1-mL subretinal injection of 1011 genome particles during vitrectomy into 1 eye randomly assigned to receive treatment. MAIN OUTCOMES AND MEASURES: Primary end point was change in best-corrected visual acuity (BCVA) on the Early Treatment Diabetic Retinopathy Study chart from baseline to month 24 in the treated eye vs the control eye. Secondary end points included microperimetry variables, change in fundus autofluorescence, and spectral-domain optical coherence tomographic evaluations from baseline to month 24 in the treated eye vs the control eye. RESULTS: On enrollment, the mean (SD) age of the 6 men included in the study was 54.9 (4.1) years. The mean (SD) BCVA score was 60.3 (13.4) (approximately 20/63 Snellen equivalent) in the study eyes and 69.3 (20.6) (approximately 20/40 Snellen equivalent) in the control eyes. At 24 months, the BCVA change was 3.7 (7.5) in the treated eyes and 0.0 (5.1) in the control eyes (difference, 3.7; 95% CI, -7.2 to 14.5; P = .43). Mean change in retinal sensitivity was 10.3 (5.5) dB in the treated eyes and 9.7 (4.9) dB in the control eyes (difference, 0.6; 95% CI, -10.2 to 11.4; P = .74). A total of 28 adverse events were reported; all were consistent with the surgical procedure (eg, conjunctival hyperemia, foreign body sensation), and none were regarded as severe. CONCLUSIONS AND RELEVANCE: Among 6 participants, gene therapy with AAV2-REP1 was associated with maintenance or improvement of visual acuity, although no significant difference was found from control eyes. All safety issues were associated with the surgical procedure and none were judged severe. Continued investigations could more precisely define the efficacy and safety of gene therapy with AAV2-REP1 in CHM. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02671539.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Fischer MD, Ochakovski GA, Beier B, et al. Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 31465092. doi:10.1001/jamaophthalmol.2019.3278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。